Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 18, 2025
Product Development

2025 catalysts: New I&I indications take center stage

Inflammation and immunology readouts to define new priority indications, modality opportunities in immune reset
BioCentury | Dec 4, 2020
Product Development

Dec. 3 Quick Takes: Moderna, NIH tout persisting neutralizing antibodies from COVID vaccine; plus Bayer, Galapagos, Braeburn, J&J and Equillium

Three-month immunity data for Moderna, NIH COVID vaccineNIH reported in The New England Journal of Medicine that all 34 Phase I subjects who received two doses of 100 ug mRNA-1273 from Moderna
BioCentury | Aug 1, 2020
Product Development

Will Biocon’s COVID-19 anti-inflammatory succeed where IL-6 blockers have failed?

Biocon is ramping up manufacturing of Alzumab as it prepares to start a large study of the drug
BioCentury | Oct 19, 2018
Financial News

Equillium prices $65.4M IPO

BioCentury | Oct 4, 2018
Distillery Therapeutics

Cancer

BioCentury | Sep 21, 2018
Financial News

Equillium proposes $86.3M IPO

BioCentury | Aug 2, 2017
Preclinical News

CDCP1 identified as potential autoimmune target

BioCentury | Feb 22, 2017
Distillery Therapeutics

Autoimmune disease

Items per page:
1 - 10 of 28
Help Center
Username
Request a Demo
Request Training
Ask a Question